NEW

The Joint Commission Promotes Psychosocial Well-being of Health Care Professionals

Health care workers in the U.S. have been facing the COVID-19 pandemic for more than three months now. Stressors such as insufficient personal protective equipment (PPE), fears of infection, feelings of isolation from family, and harassment from the community for...

EA Health and Synergy Surgicalists Announce Business Merger

Synergy Surgicalists – one of the nation's top providers of orthopedic and general surgicalist staffing for hospitals – and EA Health – a leading provider of physician staffing services and specialty physician on-call compensation solutions – have announced a business...

Surgery Exchange Launches Surgery Exchange Network

To cut down on inefficiencies and waste associated with implant procedures, Surgery Exchange is offering enhanced visibility and cost savings to device manufacturers. Surgery Exchange is a specialized suite of software solutions designed to support hospitals with...

SETi Plans Online Sales for Surface Disinfection Device and Portable Air Purifier with Violeds Technology

Sensor Electronic Technology Inc. (“SETi”), the first compound semiconductor for UV LED solutions (Violeds) and Seoul Viosys’ subsidiary, launches portable air purifiers of brand “VAC” and surface disinfection devices of brand “VSM+” with Violeds technology to reduce...

BD Receives FDA Approval for Fully Sterile Chlorhexidine Gluconate Antiseptic Skin Preparation

New BD ChloraPrep™ Skin Preparation is the Only Commercially Available CHG Antiseptic Skin Preparation with Sterile Solution Designation in the U.S.

(PRNewsfoto/BD (Becton, Dickinson and Compa)

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for BD ChloraPrep™ skin preparation with sterile solution, the only fully sterile chlorhexidine gluconate (CHG) antiseptic skin preparation commercially available in the U.S.

This new BD ChloraPrep™ product uses a proprietary and patented process to sterilize the antiseptic solution inside the sealed ampoules located in the BD applicator. With the new sterilization process in place, the BD ChloraPrep™ solutions portfolio that undergo this proprietary added level of sterility will now be labeled as a “sterile solution” on all packaging.

“At BD, we are constantly exploring new opportunities to protect patients and advance health,” said Michael Garrison, worldwide president of Surgery at BD. “The FDA approval of BD ChloraPrep antiseptic skin preparation with sterile solution ensures that the solution inside of the applicator receives the same level of sterilization as the applicator itself to help further reduce the risk of intrinsic contamination.”

Following FDA hearings in 2012 focused on sterility of skin antiseptic products and subsequent label changes in 2013, BD determined to proactively address the sterilization challenge in the U.S. Over the last six years, BD has invested in the development of an innovative sterilization process that not only can handle the volume of product demanded, but also improves overall efficiency versus traditional sterilization methods.[i]

“The idea of contaminated antiseptic solutions seems counter-intuitive because the function of an antiseptic is to kill bacteria,” said Donald E. Fry, M.D., a nationally recognized expert in infection prevention. “Outbreaks of highly resistant bacteria and spore contamination have been reported with contaminated antiseptic products in the past. Now with a fully sterilized skin preparation product, BD is assisting health care providers with a tool to enhance patient safety by the reduction of risk from intrinsic contamination in antiseptic solutions.”

Novel Sterilization Process

BD’s proprietary sterilization process was designed to achieve a minimum sterility assurance level (SAL) of 10-6, the same level required for injectable products.1 The SAL indicates there is less than 1 in 1 million chance that a sterile BD ChloraPrep™ applicator containing sterile solution will contain a single, viable microorganism following terminal sterilization of the ampoules through BD’s new sterilization process.1 While a product labeled as non-sterile does not suggest that it is contaminated with bacteria, it indicates that the contents have not been sterilized individually. Traditionally, BD ChloraPrep™ applicators have been sterilized at the end of the manufacturing process and the solution inside of the applicators was not treated with a separate sterilization process. This new process adds another layer of assurance to an already-proven product and builds on the heritage and reliability of BD ChloraPrep™ skin preparation.

The new BD ChloraPrep™ sterile solution will include a mark to indicate that it is sterile. Though not required by the FDA, BD developed this mark to distinguish sterile solution from non-sterile antiseptic skin preparations. In 2013, the FDA asked manufacturers to voluntarily change labeling on products (sterile vs. non-sterile) to further educate customers on the issue.

As a leader in antiseptic skin preparation and patient pre-operative skin preparation, BD is continually working to improve technology and patient safety. BD ChloraPrep™ skin preparation continues to be the leading standard of care for preoperative antiseptic skin preparations. Since its introduction over 18 years ago, more than four billion applicators have been used. BD ChloraPrep™ skin preparation, and its efficacy, is supported by more than 50 clinical publications.

[i] Degala, et al. United States Patent 9,078,934. July 14, 2015.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X